Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aprocitentan - Idorsia Pharmaceuticals

Drug Profile

Aprocitentan - Idorsia Pharmaceuticals

Alternative Names: AC 080; ACT-132577; JERAYGO; JNJ-2820; TRYVIO

Latest Information Update: 02 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Idorsia Pharmaceuticals
  • Class Amides; Antihypertensives; Cardiovascular therapies; Ethers; Halogenated hydrocarbons; Pyrimidines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Hypertension
  • Phase II Essential hypertension

Most Recent Events

  • 26 Apr 2024 The Committee for Medicinal Products for Human Use recommends approval of aprocitentan for Hypertension in European Union
  • 22 Mar 2024 Idorsia Pharmaceuticals has patent protection for the process of manufacture and use of Aprocitentan in USA and rest of the World (Idorsia Pharmaceuticals website, March 2024)
  • 20 Mar 2024 Idorsia Pharmaceuticals plans to launch aprocitentan for Hypertension in USA in the second half of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top